Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Glenmark and BeiGene Forge Partnership to Market and Distribute Tislelizumab and Zanubrutinib in India

NextEdge Admin

21 May 2024

2 min 57 sec

Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd., has forged an exclusive agreement with BeiGene, a renowned oncology company, to market and distribute their cutting-edge oncology medications, Tislelizumab and Zanubrutinib, in India.

Alok Malik, President and Business Head at Glenmark Pharmaceuticals Ltd., expressed enthusiasm about this collaboration, highlighting their dedication to advancing healthcare in India and providing access to innovative therapies for cancer patients. Adam Roach, Vice President and Head of Asia-Pacific at BeiGene, echoed this sentiment, emphasizing their joint mission to enhance healthcare accessibility across Asia, particularly in addressing India’s rising cancer burden.

India’s staggering population and growing cancer rates underscore the timeliness of this partnership. With projections indicating a significant increase in cancer cases by 2040, initiatives like this are crucial to meet the escalating healthcare demands. Currently, cancer claims approximately 900,000 lives annually in India, with blood cancer emerging as a major concern, affecting thousands each year.

Tislelizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1), and Zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, offer promising therapeutic avenues. Tislelizumab enhances the body’s immune response against tumors, while Zanubrutinib inhibits the proliferation of malignant B cells, presenting new possibilities for cancer treatment.

Glenmark Pharmaceuticals Ltd., a global pharmaceutical company with a focus on respiratory, dermatology, and oncology, is committed to research and innovation. Their extensive presence across various therapeutic segments and global operations reflect their dedication to addressing unmet medical needs. Likewise, BeiGene’s commitment to developing affordable and accessible oncology treatments aligns with the goal of improving healthcare worldwide.

In summary, the collaboration between Glenmark and BeiGene represents a significant step towards addressing India’s growing cancer burden. By bringing innovative oncology therapies to the Indian market, they aim to provide hope and improved outcomes for patients battling this formidable disease.